COCRYSTAL PHARMA NEW O.N. Cash Flow Conversion Efficiency
COCRYSTAL PHARMA NEW O.N. cash flow conversion efficiency. Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) has a cash flow conversion efficiency ratio of -0.274x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.74 Million ≈ $-2.03 Million USD) by net assets (€6.33 Million ≈ $7.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of COCRYSTAL PHARMA NEW O.N. (2021–2025)
Cash flow conversion efficiency of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of COCRYSTAL PHARMA NEW O.N. for real-time trading data and today's change.
COCRYSTAL PHARMA NEW O.N. Cash Flow Conversion Ratio Explained
COCRYSTAL PHARMA NEW O.N. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
COCRYSTAL PHARMA NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COCRYSTAL PHARMA NEW O.N. ranked by their cash flow conversion efficiency. Also see COCRYSTAL PHARMA NEW O.N. (8CC) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Malpac Holdings Bhd
KLSE:4936
|
0.000x |
|
OPG POWER VENTURES (OPB.SG)
STU:OPB
|
N/A |
|
Thanasiri Group Public Company Limited
BK:THANA
|
0.024x |
|
Stallion Uranium Corp.
V:STUD
|
-0.034x |
|
Biotechnology Assets S.A.
MC:BST
|
0.102x |
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
-0.165x |
|
Arcoma AB
ST:ARCOMA
|
0.001x |
|
Bravada Gold Corporation
V:BVA
|
-0.213x |
Annual Cash Flow Conversion Efficiency for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. Review COCRYSTAL PHARMA NEW O.N. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.33 Million ≈ $7.40 Million |
€-8.19 Million ≈ $-9.58 Million |
-1.294x | +25.25% |
| 2024-12-31 | €9.52 Million ≈ $11.13 Million |
€-16.48 Million ≈ $-19.27 Million |
-1.731x | -211.42% |
| 2023-12-31 | €26.38 Million ≈ $30.85 Million |
€-14.67 Million ≈ $-17.15 Million |
-0.556x | -2.61% |
| 2022-12-31 | €39.57 Million ≈ $46.26 Million |
€-21.43 Million ≈ $-25.06 Million |
-0.542x | -230.30% |
| 2021-12-31 | €77.55 Million ≈ $90.66 Million |
€-12.72 Million ≈ $-14.87 Million |
-0.164x | -- |
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more